• 1
    Bhatt DL. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. Am J Cardiol 2009; 103(Suppl.): 11A9A.
  • 2
    Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 46672.
  • 3
    Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R et al. Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 91933.
  • 4
    Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel J Thromb Haemost 2010; 8: 4828.
  • 5
    Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 8418.
  • 6
    Korporaal SJA, Akkerman JW. Platelet activation by low density lipoproteins and high density lipoproteins. Pathophysiol Haemost Thromb 2006; 35: 27080.
  • 7
    Nofer JR, Walter M, Kehrel B, Wierwille S, Tepel M, Seedorf U, Assmann G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide– derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998; 18: 8619.
  • 8
    Vergani CG, Plancher AC, Zuin M, Cattaneo M, Tramaloni C, Maccari S, Roma P, Catapano AL. Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). Eur J Clin Invest 1984; 14: 4954.
  • 9
    Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84: 10117.
  • 10
    Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004; 11: 4129.
  • 11
    Petraki MP, Mantani PT, Tselepis AD. Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides. Curr Pharm Design 2009; 15: 314666.
  • 12
    Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 37192.
  • 13
    Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 68995.
  • 14
    Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299: 126576.
  • 15
    Mackness B, Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation 2003; 107: 27759.
  • 16
    Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, Bard JM, Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996; 126: 299303.
  • 17
    Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz H-G, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Νature Μed 2011; 1: 1106.
  • 18
    Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schomig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32: 160513.
  • 19
    Kalantzi KI, Dimitriou AA, Milionis HJ, Goudevenos IA, Tselepis AD. Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. J Thromb Haemost 2011; 4: 8758.
  • 20
    Mitsios JV, Tambaki AP, Abatzis M, Biris N, Sakarellos-Daitsiotis M, Sakarellos C, Soteriadou K, Goudevenos J, Elisaf M, Tsoukatos D, Tsikaris V, Tselepis AD. Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3. Eur J Biochem 2004; 271: 85562.
  • 21
    Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 140411.
  • 22
    Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 19828.
  • 23
    Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 13358.
  • 24
    Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002; 22: 30611.
  • 25
    Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD. The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res 2003; 44: 191926.
  • 26
    Tsimihodimos V, Karabina S-A, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of platelet activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002; 43: 25663.
  • 27
    Ferre N, Tous M, Paul A, Zamora A, Vendrell J, Bardaji A, Camps J, Richart C, Joven J. Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 2002; 35: 197203.
  • 28
    Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93102.
  • 29
    Brodde MF, Korporaal SJA, Herminghaus G, Fobker M, Van Berkel TJC, Tietge UJF, Robeneck H, van Eck M, Kehrel BE, Nofer JR. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI. Role of negatively charged phospholipids. Atherosclerosis 2011; 215: 37482.
  • 30
    Korporaal SJA, Illiana M, Hauer AD, Hildebrand RB, Hoekstra M, ten Cate H, Praticò D, Akkerman J-WN, van Berkel TJC, Kuiper J, van Eck M. Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscler Thromb Vasc Biol 2011; 31: 3442.
  • 31
    Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within one month of treatment. Platelets 2011; doi:10.3109/09537104.2011.597527.
  • 32
    Palmerini T, Barozzi C, Tomasi L, Sangiorgi D, Marzocchi A, De Servi S, Ortolani P, Bacchi Reggiani L, Alessi L, Lauria G, Bassi M, Branzi A. A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res 2010; 125: 30914.
  • 33
    Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet J-P, Montalescot G, Cazenave J-P, Dickele M-C, Monassier J-P, Gachet C. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the vasp-02 (vasodilator-stimulated phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1: 6318.
  • 34
    von Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, Graf I, Schömig A. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 18149.
  • 35
    Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 13129.
  • 36
    Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 36375.
  • 37
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome P-450 Polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 35462.
  • 38
    von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005; 112: 294650.
  • 39
    Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010; 16: 380814.
  • 40
    Papathanasiou A, Goudevenos J, Tselepis AD. Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact. Curr Pharm Des 2009; 15: 108594.